Hiroshi Ureshino

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

Shinya Kimura, Jun Imagawa, Kazunori Murai et al. · The Lancet Haematology · 2020 · 100 citations

Hematological Malignancy, Medicine, First-line Dadi Trial +9

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

Kazunori Murai, Hiroshi Ureshino, Takashi Kumagai et al. · The Lancet Haematology · 2021 · 60 citations

Chronic Phase, Low-dose Dasatinib, Hematological Malignancy +8

Clinical impact of the CONUT score in patients with multiple myeloma

Sho Okamoto, Hiroshi Ureshino, Keisuke Kidoguchi et al. · Annals of Hematology · 2019 · 50 citations

Hematological Malignancy, Health Sciences, Medicine +7

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

Tatsuro Watanabe, Satoshi Yamashita, Hiroshi Ureshino et al. · Blood · 2020 · 49 citations · Full text

Allelic Polymorphisms of <i>KIR</i> s and <i>HLA</i> s Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML

Hiroshi Ureshino, Takero Shindo, Hiroto Kojima et al. · Cancer Immunology Research · 2018 · 36 citations